Boxei Squibb announces CheckMate870 clinical study reaches key research end, no new safety signals found

On May 15, 2020, TimeMes Guibao (NYSE: BMY) announced that the CheckMate 870 study had reached its main end in clinical researchCheckMate 870 is an open labeled Phase IIIB clinical study designed to assess the safety and effectiveness of odivist use in patients with advanced non-small cell lung cancer after 1-2 systematic treatmentsThe study included 400 Asian patients, 394 of whom were Chinese, and the main focus of the study was to assess the incidence of high-level (3-5 level) adverse reactions in patients with treated non-small cell lung cancer with advanced non-HBV infectionThe study used 240 mg of fixed dose and 30-minute intravenous infusion (every two weeks) until the patient developed disease progression or intolerance, or for a maximum duration of 24 monthsThe results showed that the safety characteristics of Odivo in the treated population were consistent with previous key studies based on weight doses, and no new safety signals were foundThe CheckMate-870 study's intended treatment population included not only PD-L1 to 1% and 1% of patients, but also some patients with EGFR/ALK mutations and HBV infectionsThe safety and efficacy of treatment was also shown in patients with EGFR mutations and HBV infections in OdivoThe detailed findings of the CheckMate-870 will be presented at the International Medical Conference in the near future"The prospective use of fixed doses and short-term infusions in large samples of Asian patients with a large sample of Chinese patients confirms that the program can also benefit patients from treatment," said Professor Lu Wei, lead researcher at CheckMate-870 and director of oncology at Shanghai Jiaotong University's affiliated chest hospitalAt the same time, the benefits of eGFR/ALK mutation and HBV infection in China have been studied, which provides reliable data support for the treatment of this special population, fills the research gap of tumor immunotherapy, and gives more patients with advanced lung cancer the opportunity to receive innovative treatment"With the widespread use of cancer immunotherapy in China and Asia, the safety, effectiveness and convenience of treatment are the focus of continuous attention," said DrHong Xuxuan, head of regional medicine affairs for China and Asia,The findings of CheckMate-870 once again validate the safety and efficacy of Odivo in Asians, especially in patients with advanced NSCLC in China, and provide new treatment ideas for the treatment of advanced lung cancer by improving the convenience of clinical useAs the first company to bring cancer immunotherapy to China, Boxei Is a Constantly Explore and Optimize Treatment Options to Help Patients Overcome Serious Diseaseson the CheckMate 870 studyCheckMate 870 is an open-label Phase IIIb clinical study that includes 400 cases of Asian non-small cell lung cancer patients with mainly Chinese patients (394 cases in China), and evaluates Odivo Single Drug 2 40 mg, 30-minute intravenous infusion, administered every 2 weeks for the effectiveness and safety of patients with advanced non-small cell lung cancer (NSCLC) who have undergone 1-2 systematic treatments, including squamous and non-squamous cancer patients the study included 400 patients with advanced or metastatic scaly and non-scale NSCLC, including 44 patients with EGFR/ALK mutations who had received two systematic treatments, including TKI targeted drugs and chemotherapy, and 17 patients with HBV DNA 500 IU/ml of HBV virus infection All patients received 240 mg, 30 minutes, intravenous infusion every two weeks, until the disease progressed or intolerable toxicity occurred, for up to 24 months of treatment studies focused on the assessment of high-level (3-5 level) adverse reactions in patients with non-HBV infection Secondary research endpoints include: safety in patients with HBV infection, safety of all patients, and the effectiveness of different pathological histological types, including OS (total lifetime), ORR (objective remission), PFS (no progression survival), and PD-L1 expression and HBV infection status The study also carried out exploratory analysis on the following aspects: pharmacoeconomics, HBV DNA changes in patients infected with hepatitis B, patient reportoutcomes, biomarkers, etc Source: